Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 12/20 | 0.58 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12330925 | 0.83 | TLR8 (0.47) | TLR8TLR7KMT2AKDM4ENPSR1 | |
| SCHEMBL12330861 | 0.83 | TLR8 (0.46) | TLR8TLR7KMT2AKDM4ENPSR1 | |
| SCHEMBL12330648 | 0.80 | TLR8 (0.44) | TLR8TLR7KMT2AL3MBTL1 | |
| SCHEMBL15764603 | 0.80 | LMNA (0.48) | TLR8TLR7KMT2APDE10A | |
| SCHEMBL6416393 | 0.79 | TLR8 (0.90) | TLR8TLR7 | |
| SCHEMBL10005092 | 0.79 | KMT2A (0.54) | TLR8TLR7KMT2AKDM4ENPSR1 | |
| SCHEMBL12330665 | 0.75 | TLR8 (0.47) | TLR8TLR7 | |
| SCHEMBL12330866 | 0.75 | TLR8 (0.38) | TLR8TLR7PDE10A | |
| SCHEMBL20434274 | 0.74 | TLR8 (1.00) | TLR8TLR7 | |
| SCHEMBL12330926 | 0.73 | TLR8 (0.38) | TLR8TLR7KMT2APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951866-B2 | Bicyclic pyrimidine compounds and therapeutic use thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-10-04 | — | — | US | disclosed |
| EP-1110951-B1 | PYRIMIDINE DERIVATIVES | SUMITOMO PHARMA (JP) | 2004-05-19 | — | — | EP | disclosed |
| US-20030105323-A1 | Pyrimidine derivative | SUMITOMO PHARMACEUTICALS COMPANY LIMITED | 2003-06-05 | — | — | US | disclosed |
| US-6458798-B1 | HAS AN INHIBITORY ACTIVITY OF PRODUCTION OF TH2 TYPE CYTOKINES SUCH AS IL-4, IL-5, ETC., AND IS USEFUL AS AN THERAPEUTIC AGENT FOR ALLERGIC DISEASES, AUTOIMMUNE DISEASES SUCH AS SYSTEMIC LUPUS ERYTHEMATHOSUS, ETC., AND ACQUIRED | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-10-01 | — | — | US | disclosed |
| EP-1110951-A1 | PYRIMIDINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105323-A1 | Pyrimidine derivative | IL5, IL4, IL15 | TLR8 209/4885TLR7 97/4885KMT2A 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.